Skip to main content

Table 8 Serious clinical adverse experiences irrespective of relationship to study drug that occurred at an incidence rate of ≥0.2% in any group

From: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

  Sitagliptin 100 mg
n (%)
(N = 3415)
Non-Exposed
n (%)
(N = 2724)
Difference between Sitagliptin
and Non-Exposed
% (95% CI)*
Coronary Artery Disease 5 (0.1) 7 (0.3) -0.1 (-0.4, 0.1)
Myocardial Infarction 4 (0.1) 5 (0.2) -0.1(-0.3, 0.1)
Non-cardiac Chest Pain 4 (0.1) 9 (0.3) -0.2 (-0.5, 0.0)
Cholelithiasis 6 (0.2) 2 (0.1) 0.1 (-0.1, 0.3)
Pneumonia 4 (0.1) 5 (0.2) -0.1 (-0.3, 0.1)
  1. CI = confidence interval
  2. *Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.